Werewolf Therapeutics financials
$0.9100−2.15%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $21.0M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $1.1M | $742.0K | $1.5M | $5.9M |
| Gross profit | $21.0M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $1.1M | $742.0K | $1.5M | $5.9M |
| Gross margin | 100.0% | — | — | — | — | — | — | — | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating income | $7.2M | -$13.3M | -$9.4M | -$15.7M | -$17.5M | -$18.0M | -$20.3M | -$17.1M | -$19.0M | -$17.2M | -$13.0M | -$9.3M |
| Net income | $3.7M | -$13.5M | -$8.4M | -$16.4M | -$18.0M | -$18.1M | -$20.4M | -$16.7M | -$17.2M | -$16.2M | -$12.0M | -$8.3M |
| Net margin | 17.5% | — | — | — | — | — | — | — | −1509.1% | −2182.3% | −799.7% | −140.5% |
| Diluted EPS | $0.08 | $-0.28 | $-0.16 | $-0.36 | $-0.40 | $-0.40 | $-0.44 | $-0.38 | $-0.43 | $-0.39 | $-0.33 | $-0.23 |
| EBITDA | $9.6M | -$12.9M | -$9.0M | -$15.3M | -$17.1M | -$17.6M | -$19.9M | -$16.7M | -$18.5M | -$16.7M | -$12.5M | -$8.8M |
| Operating cash flow | $6.6M | -$10.6M | -$11.0M | -$15.2M | -$15.2M | -$18.9M | -$14.3M | -$12.5M | -$14.2M | -$15.3M | -$4.6M | -$7.2M |
| Free cash flow | $6.6M | -$10.6M | -$11.0M | -$15.2M | -$15.2M | -$18.9M | -$14.4M | -$12.5M | -$14.2M | -$15.4M | -$4.8M | -$7.4M |
| Diluted shares | 48.6M | 49.4M | 51.6M | 45.8M | 45.0M | 44.8M | 46.1M | 43.7M | 44.0M | 41.6M | 36.6M | 35.7M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $22.0M | $46.5M | $57.0M | $65.7M | $77.6M | $92.0M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $0.00 | $28.8M | $28.2M | $27.7M | $27.1M | $26.6M |
| Total assets | $24.2M | $58.0M | $69.4M | $79.6M | $92.6M | $107.2M |
| Total liabilities | $7.9M | $45.8M | $44.6M | $50.0M | $51.1M | $49.9M |
| Shareholders' equity | $16.3M | $12.2M | $24.8M | $29.6M | $41.5M | $57.3M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology